|Videos|July 14, 2015
Potential Change in Guidelines for Ticagrelor Therapy
Advertisement
Episodes in this series
The results of the PEGASUS-TIMI 54 trial could potentially lead to a change in clinical guidelines to extend the currently recommended 12 months of ticagrelor therapy.
This change would be contingent on patients’ ability to tolerate ticagrelor therapy beyond 12 months and through 33 months, which was the average follow-up in the PEGASUS-TIMI 54 trial.
Comparing the PEGASUS-TIMI 54 trial with the DAPT study, Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, a clinical specialist of cardiovascular medicine at Saint Barnabas Medical Center, notes the population in the former study included a more real-to-life population of higher-risk patients.
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
Ramantamig's 93.6% ORR and Outpatient CRS Control
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5